ReWalker Sets Guinness World Record for Climbing a London Skyscraper While Wearing an Exoskeleton
Simon Kindleysides is first paralyzed man to climb a 51-story skyscraper; earns his second Guinness World Record using his ReWalk Personal Exoskeleton
Simon Kindleysides atop Leadenhall Skyscraper in his ReWalk Exoskeleton
MARLBOROUGH, Mass. and LONDON, March 24, 2022 (GLOBE NEWSWIRE) — ReWalk Robotics, Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced Simon Kindleysides, a British man who is paralyzed from the waist down due to an inoperable brain tumor, has earned a Guinness World Record after climbing to the top of London’s Leadenhall Building while wearing the company’s wearable robotic exoskeleton.
It took Kindleysides six hours and 16 minutes to climb the 1,444 steps, a grand total of 51 stories, from the basement to the very top of the skyscraper. Leadenhall, which is also known as “The Cheesegrater” because of its unique design, is 225 meters tall and a standout in the London skyline. This is Kindleysides’ second time landing in the Guinness Book of World Records. He set his first record in 2018 when he became the first paralyzed man to walk the London Marathon in an exoskeleton suit.
“I use my suit to push boundaries to the max,” said Kindleysides. “I don’t just use it for a walking aid. I’ve pushed the suit to its absolute limits. I encourage anyone out there who wants to try new things to just do it. My motto is ‘no such thing as can’t.’”
The ReWalk system stair function, which is available in the UK, EU, and other international locations (excluding US), allows a user to climb and descend stairs or curbs.
“The entire ReWalk team would like to congratulate Simon on his amazing accomplishment,” said Larry Jasinski, CEO of ReWalk. “His dedication, physical fitness, and determination are truly impressive. The durability and safety of the ReWalk design have again been demonstrated through user experience and we are glad our suit – which is the only exoskeleton approved for use on stairs overseas – allowed him to complete this difficult challenge. It is used every day by ReWalkers and their companions on stairs and curbs within the EU and we hope to bring the stairs function to the U.S. market soon so that all ReWalkers can have access to full functionality of their exoskeleton.”
Kindleysides is taking on the London Marathon again in October, where he hopes to beat his own Guinness World Record.
For more information on ReWalk Robotics and the ReWalk exoskeleton, visit rewalk.com.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the United States.
ReStore® is a registered trademark of ReWalk Robotics Ltd. in the United States, Europe and the United Kingdom.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding ReWalk’s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: uncertainties associated with future clinical trials and the clinical development process, the product development process and U.S. Food and Drug Administration (“FDA”) regulatory submission review and approval process; the adverse effect that the COVID-19 pandemic has had and may continue to have on the Company’s business and results of operations; ReWalk’s ability to have sufficient funds to meet certain future capital requirements, which could impair the Company’s efforts to develop and commercialize existing and new products; ReWalk’s ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk’s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk’s ability to achieve reimbursement from third-party payors, including the Centers for Medicare & Medicaid Services (CMS), for its products; ReWalk’s limited operating history and its ability to leverage its sales, marketing and training infrastructure; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; ReWalk’s ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; ReWalk’s ability to improve its products and develop new products; ReWalk’s ability to obtain clearance from the FDA for use of the ReWalk Personal device on stairs; ReWalk’s compliance with medical device reporting regulations to report adverse events involving its products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on ReWalk’s ability to market and sell its products; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of ReWalk’s IT systems significantly disrupting its business operations; ReWalk’s ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading “Risk Factors” in ReWalk’s annual report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9c95b2be-fc4c-49e9-82c8-840d3435a66e
CONTACT: ReWalk Media Relations: Jennifer Wlach E: media@rewalk.com ReWalk Investor Contact: Almog Adar Director of Finance ReWalk Robotics Ltd. T: +972-4-9590130 E: investorrelations@rewalk.com
